Gastritis

Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients

Retrieved on: 
Tuesday, February 13, 2024
Urinary tract infection, Gastroesophageal reflux disease, Research, Heartburn, Toxicity, Magnesium, Polyp, Liver, CYP, CGA, Achlorhydria, Esophagitis, Patient, PBM, Vitamin B12, Vonoprazan, Kidney, Spine, Lactation, Absorption, Hypokalemia, SCAR, Calcium, Express Scripts, TIN, Endoscopy, Tablet, Express, Magnesium deficiency, Hypocalcemia, Diarrhea, Hypersensitivity, Physician, Gastritis, Malabsorption, GERD, PPI, Hypertension, SJS, Enzyme inhibitor, EGFR, Stevens–Johnson syndrome, Indigestion, Nelfinavir, Clostridioides, Abdominal pain, Hip, Pharmacy, Enzyme, Glomus tumor, FDA, CDAD, Atazanavir, Risk, BMJ Open, Wrist, Drug, Impairment, Pharmaceutical industry

Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.

Key Points: 
  • Given that most Erosive GERD patients have already undergone treatment with a PPI, and many continue to express dissatisfaction with their current regimens, we are pleased with this outcome.
  • doi:10.1136/ bmjgast-2022-000941
    VOQUEZNA® (vonoprazan) is a potassium-competitive acid blocker (PCAB) indicated:
    for the healing of all grades of Erosive Esophagitis (Erosive Gastroesophageal Reflux Disease or Erosive GERD) and relief of heartburn associated with Erosive GERD in adults.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.
  • Renal Impairment: For the healing of Erosive GERD, dosage reduction is recommended in patients with severe renal impairment (eGFR

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urea, Medical Subject Headings, Marketing, European Commission, INN, Stomach, Heartburn, Infection, Allergy, Bloating, ATC, Helicobacter pylori, International, European, Nausea, Language, Inflammation, Duodenum, Laboratory, Water, Mass spectrometry, Indigestion, Peptic ulcer disease, Gastritis, Medication, Enzyme, Select, Committee, Patient, Carbon, Ammonia, Diagnosis, Anatomy, Medicine, Ulcer, Nature, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Pylobactell, 13C-urea, Date of authorisation: 07/05/1998, Revision: 12, Status: Authorised

Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD

Retrieved on: 
Wednesday, December 6, 2023
Quality of life, CYP, Kidney, Risk, Heartburn, Enzyme inhibitor, FDA, TIN, Hypertension, Achlorhydria, Magnesium, Liver, PPI, SJS, Magnesium deficiency, Chest pain, Atazanavir, Endoscopy, Impairment, SCAR, Vitamin B12, Malabsorption, Absorption, PDUFA, CDAD, Calcium, New Drug Application, Gastritis, Enzyme, Food and Drug Administration, Clostridioides, Vonoprazan, Patient, Hip, Hypokalemia, Food, Polyp, GERD, Nelfinavir, Toxicity, EGFR, Wrist, Diarrhea, Hypocalcemia, NDA, Abdominal pain, Urinary tract infection, Hypersensitivity, Stevens–Johnson syndrome, Glomus tumor, Spine, Indigestion, Drug, CGA, Lactation, Pharmaceutical industry

The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.

Key Points: 
  • The FDA has assigned the application a standard 10-month review with a Prescription Drug User Fee Act (PDUFA) target action date of July 19, 2024.
  • “Non-Erosive GERD represents a substantial segment of the U.S. GERD population, affecting millions of individuals and impacting their quality of life.
  • Symptoms impact overall quality of life and can include episodic heartburn, especially at night, regurgitation, problems swallowing, and chest pain.
  • for the maintenance of healing of all grades of Erosive GERD and relief of heartburn associated with Erosive GERD in adults.

Home for the Holidays -- DispatchHealth Delivers Emergency Room Magic to Your Living Room

Retrieved on: 
Sunday, December 24, 2023
Patient, Risk, Heartburn, Health, Intravenous therapy, Individual, Nurse practitioner, Visit, Infection, Allergy, Asthma, Ill, COVID-19, Gastritis, Diagnosis, Nursing

Traditionally, emergency rooms (ER) have been the go-to destination for holiday health mishaps; however, DispatchHealth offers another option for urgent medical care—one that delivers healthcare right to patients' doorsteps.

Key Points: 
  • Traditionally, emergency rooms (ER) have been the go-to destination for holiday health mishaps; however, DispatchHealth offers another option for urgent medical care—one that delivers healthcare right to patients' doorsteps.
  • "Patients can receive treatment in the comfort of home, allowing them to enjoy precious family time."
  • DispatchHealth is primed to combat these health risks through prompt, on-site medical services, including testing, diagnosis, and treatment initiation.
  • See DispatchHealth Team in Action and Learn More from our Experts: Video Link
    Video News Release: BROLL and Individual Interview Sound Bites Available Upon Request.

United States Transdermal Patch Market Report 2023: Dosage, Price & Clinical Trials Insights to 2029 - Focus on Opioid, Cardiovascular Diseases, Neurological Disorders, and Hormonal Therapy - ResearchAndMarkets.com

Retrieved on: 
Thursday, November 23, 2023
Medical Devices, Health, Gastritis, Brown University, Transdermal patch, Research, Indication, Chronic pain, Parkinson's disease, Pain management, Buprenorphine, University of California, Davis, Pregnancy, Patient, FDA, Alzheimer's disease, Opioid use disorder, Zydus Lifesciences, University, Cancer, Communication, Pain, Growth, Nerve, DSM-IV codes, Generic drug, Pharmaceutical industry, Adhesive, Birth control

The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029" report has been added to ResearchAndMarkets.com's offering.
  • With the rapid approvals of transdermal patches lately, the FDA has also marked itself as an important player in the US market of transdermal patches.
  • The FDA provides a detailed communication on the requirements of an ideal transdermal patch, and patches that meet these are allowed entry in the regional market.
  • US Transdermal Patch Market, Dosage, Price & Clinical Trials Insight 2029 Report Highlights:
    US Transdermal Patch Market Opportunity: > US$ 5 Billion By 2029
    Commercially available Patches In US Market: > 25 Patches
    Ongoing Clinical Trials Of Transdermal Patches in US: > 40 Patches
    US Transdermal Patch Clinical Trials Insight By Company, Indication & Phase

The Inner Circle Acknowledges, Dr. Eugene H. Lewis III as a Life Achiever 2023 for his contributions to the field of Pathology

Retrieved on: 
Monday, December 4, 2023
Inner circle, Associate, Pernicious anemia, Medical director, Medical Center, Memorial, Gastritis, Medicine, College, Life, Student, Patient, Multimedia, Hartford Hospital, American Board of Pathology, Mentorship, University, Cancer, Doctor of Philosophy, Quinnipiac University, Family, Physician, St. Vincent's HealthCare, Education, Cystic fibrosis, Medical device, Pathology

FAIRFIELD, Conn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Eugene H. Lewis III is acknowledged as a Life Achiever 2023 for his contributions to the field of Pathology.

Key Points: 
  • FAIRFIELD, Conn., Dec. 4, 2023 /PRNewswire/ -- Prominently featured in The Inner Circle, Dr. Eugene H. Lewis III is acknowledged as a Life Achiever 2023 for his contributions to the field of Pathology.
  • He completed an Anatomic and Clinical Pathology residency at Hartford Hospital from 2000 – 2004, and was Chief Resident from 2003-2004.
  • He became board certified in Clinical and Anatomic Pathology through the American Board of Pathology.
  • With more than 16 years in the field, Dr. Lewis currently practices in Bridgeport, Connecticut as a Managing Member of Fairfield County Pathology Consultants LLC.

American Regent Introduces Levocarnitine Injection, USP; FDA-Approved, "AP" Rated, and Therapeutically Equivalent to Carnitor®¹

Retrieved on: 
Tuesday, October 10, 2023
Urine, INR, Kidney disease, ESRD, Vomiting, Carnitine, Milk, Nursing, Safety, Pregnancy, Edema, Dialysis, Nausea, FDA, Warfarin, Drinking fountain, Gastritis, Child, Seizure, Anaphylaxis, Patient, Vaccine, Pharmaceutical industry, Dietary supplement

Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction.

Key Points: 
  • Consider the risks and benefits of re-administering levocarnitine to individual patients following a severe reaction.
  • Studies in dairy cows indicate that the concentration of levocarnitine in milk is increased following exogenous administration of levocarnitine.
  • You are encouraged to report adverse drug events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
  • You are encouraged to report adverse drug events (ADEs) to American Regent:
    ADEs may also be reported to the FDA:

World Maritime Day: MedSea Shares Four Important Trends in Seafarer Health

Retrieved on: 
Thursday, September 28, 2023
COVID-19, Medical Supplies, Infectious Diseases, Maritime, Transport, Dental, Professional Services, General Health, Data Analytics, Health, Exercise, Ill, International, Smoking, Habit, Drinking water, Accident, Face, Food safety, Constipation, Nutrient, RSV, Risk, Sanitation, Gastritis, International SOS, United States Secretary of Labor, Mortality, Research, Smoking cessation, Virus, Safety, Personal protective equipment, Vaccine

MedSea, an International SOS company and a leading provider of health services to thousands of seafarers worldwide, provides their top four commercial maritime health trends for the remainder of 2023.

Key Points: 
  • MedSea, an International SOS company and a leading provider of health services to thousands of seafarers worldwide, provides their top four commercial maritime health trends for the remainder of 2023.
  • In general, dental issues are preventable and can be avoided, therefore it is crucial for ship owners/operators to promote dental health onboard .
  • Smoking cessation reduces the risk of tobacco-related diseases and improves respiratory health, which is vital for those working in confined spaces.
  • Additionally, addressing alcohol abuse not only enhances seafarers’ health, but also mitigates the risk of accidents, ensuring a healthier and safer maritime environment.

Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate

Retrieved on: 
Monday, September 11, 2023
Exercise, UTI, Cranberry, Infection, CMC, Cardiovascular disease, Clinical trial, Cancer, Urinary tract infection, Woman, Research, Dentistry, Indigenous, Marketing, Helicobacter pylori, Proanthocyanidin, Peptic ulcer disease, Risk, Gastritis, Bacteria, FDA, Scurvy, System, Dietary supplement

WAREHAM, Mass., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate Wareham, Mass., September 8, 2023 – At its annual summer meeting August 14, 2023, the Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.

Key Points: 
  • The Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.
  • WAREHAM, Mass., Sept. 11, 2023 /PRNewswire-PRWeb/ -- Cranberry Marketing Committee Announces 2023 U.S. Cranberry Crop Estimate Wareham, Mass., September 8, 2023 – At its annual summer meeting August 14, 2023, the Cranberry Marketing Committee (CMC) completed its biannual exercise of estimating the next U.S. cranberry crop production with the 2023 crop expected to be 8,165,000 100-lb barrel equivalents representing a 3.6 percent increase from 2022.
  • CMC represents more than 1,200 US Cranberry Growers in the growing regions of Wisconsin, Michigan, Minnesota, Massachusetts, Rhode Island, Connecticut, New Jersey, Washington and Oregon.
  • US cranberry growers harvest cranberries annually in the fall from more than 40,000 acres of bogs and marshes.

Meridian Bioscience Continues Expansion of H. pylori Diagnostic Testing Solutions with FDA Clearance of Premier HpSA Flex

Retrieved on: 
Tuesday, July 25, 2023
Helicobacter pylori, Antigen, AACC, FLEX, Stomach, Peptic ulcer disease, Patient, Cleveland Clinic Journal of Medicine, Diagnosis, Gastritis, FDA, C&S, Medical device, Pharmaceutical industry, Meridian

CINCINNATI, July 25, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.

Key Points: 
  • CINCINNATI, July 25, 2023 /PRNewswire/ -- Meridian Bioscience, Inc., a leading global provider of diagnostic testing solutions and life science raw materials, announced today that the United States Food and Drug Administration (FDA) has cleared Premier® HpSA® FLEX™ for the diagnosis of H. pylori in both preserved and unpreserved stools.
  • Premier HpSA Flex joins the extensive Meridian H. pylori portfolio of products that includes BreathID® (urea breath test for H. pylori), Curian® HpSA (fluorescent immuno analyzer antigen test), and ImmunoCard® Stat!
  • Meridian is committed to developing the broadest range of highly accurate gastrointestinal diagnostic solutions.
  • Meridian's Premier HpSA FLEX test is a non-invasive enzyme immunoassay used to qualitatively detect Helicobacter pylori (H. pylori) specific antigens in fresh, frozen, or preserved human fecal specimens.